AstraZeneca-Sanofi Beyfortus approved in Japan for prevention of RSV disease in infants Written By Ruchika Sharma31 March 2024 12:30 PM ISTCambridge: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of...
Sanofi Gets CDSCO Panel Nod To Import, Market Nirsevimab to Treat Respiratory Syncytial Virus Disease Written By Dr. Divya Colin27 March 2024 6:00 PM ISTNew Delhi: Pharmaceutical major Sanofi Healthcare India has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Nirsevimab found Effective in Preventing RSV-Associated Hospitalizations Among Infants in new research Written By Dr.Niharika Harsha B11 March 2024 12:45 AM ISTIn a significant development in pediatric healthcare, nirsevimab, a long-acting monoclonal antibody, has demonstrated robust real-world...
AstraZeneca-Sanofi Beyfortus gets nod for RSV disease prevention in infants in China Written By Ruchika Sharma2 Jan 2024 3:06 PM ISTChina: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of...
Nirsevimab effective in preventing hospitalization for RSV associated lower RTI in infants Written By Aditi29 Dec 2023 7:00 PM ISTRespiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection in young children and infants, leading to...
AAP Recommends Nirsevimab to Protect Infants Against Severe RSV: Monoclonal Antibody Gains Traction Written By Dr. Kamal Kant Kohli18 Aug 2023 9:45 AM ISTUSA: The American Academy of Pediatrics (AAP) has released recommendations for the use of the monoclonal antibody nirsevimab for the prevention of...
AstraZeneca-Sanofi Nirsevimab unanimously recommended by USFDA Advisory Committee for prevention of RSV in infants Ruchika Sharma9 Jun 2023 1:30 PM ISTLondon: The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously 21 to 0 that AstraZeneca and...
Nirsevimab delivers 83 percent reduction in RSV infant hospitalizations in a real world clinical trial setting: Sanofi Ruchika Sharma14 May 2023 2:00 PM ISTRSV is the most common cause of LRTD, including bronchiolitis and pneumonia, in infants.
AstraZeneca, Sanofi, Sobi simplify contractual agreements for Nirsevimab Ruchika Sharma12 April 2023 3:44 PM ISTBeyfortus (nirsevimab), an investigational long-acting antibody designed to protect all infants against RSV infections from birth through their first...
Pfizer RSV vaccine 82 percent effective in severe infection in infants: Data Ruchika Sharma7 April 2023 12:30 PM ISTFDA approval could make Pfizer's shot the first maternal vaccine available to prevent the disease in infants.
Monoclonal antibody treatment improves outcomes of respiratory syncytial virus infection outcomes in infants Written By Jacinthlyn Sylvia20 Feb 2023 10:15 AM ISTWithout a discernible increase in adverse events, nirsevimab, motavizumab, and palivizumab were linked to significant improvements in the prevention...
USFDA accepts AstraZeneca’s BLA for Nirsevimab for prevention of RSV lower respiratory tract disease Ruchika Sharma7 Jan 2023 10:00 AM ISTRSV is a very contagious virus that can lead to serious respiratory illness, according to the Centers for Disease Control and Prevention.
